Share the Wealth? No Thanks

Biopharmaceutical companies are doing the math and increasingly coming to one conclusion: it's in their economic interests to buy out a biotech partner. Genentech Inc.'s $919 million all-cash acquisition of its omalizumab (Xolair) partner Tanox Inc. in November is one of the most recent examples.

By Christopher Morrison

Sharing just isn’t what it used to be.

More from Business Strategy

More from In Vivo